A Phase I, Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients.
Phase of Trial: Phase I
Latest Information Update: 01 May 2015
At a glance
- Drugs Catumaxomab (Primary)
- Indications Carcinoma
- Focus Adverse reactions
- 01 Jul 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2012 Planned End Date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.